Moderna Advancing mRNA Breakthroughs
Moderna Wins FDA Approval for mRNA Flu Vaccine and Reports Positive Melanoma Trial Results
Key Points
Intismeran autogene is a personalized mRNA therapy created after tumor sequencing to target up to 34 tumor-specific neoantigens, used after surgery in an adjuvant setting, and combined with Keytruda; the Phase 3 INTerpath-001 trial enrolled 1,137 high‑risk resected melanoma patients in a 2:1 randomization (combo vs Keytruda alone).
Phase 2b results for intismeran autogene plus Keytruda showed a substantial benefit: a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death versus Keytruda alone, with fatigue and injection-site pain around 60% and chills about 51% among recipients, and no Grade 4 or 5 treatment-related events attributed.
In the Phase 3 results, Moderna and Merck reported delays in cancer recurrence and distant metastasis, but topline numbers and overall survival data were not disclosed yet; investigators say additional endpoints, including OS, will be evaluated and reported later, reinforcing the potential for a new adjuvant post‑surgery treatment model.
Moderna’s mFLUSIVA (mRNA-1010) gained FDA approval for adults 50 and older as the first mRNA-based flu vaccine, offering a faster production path to adapt to circulating strains; the pivotal trial involved more than 40,000 adults across 11 countries and showed superiority to standard-dose vaccines by RT-PCR-confirmed flu-like illness, with accelerated approval for 65+ based on a US trial of over 2,900 participants. US availability is anticipated for the 2026–2027 season.
Moderna’s melanoma news spurred a sharp stock rally, with shares rising roughly 150% on the heels of the Phase 3 results, highlighting investor enthusiasm for an oncology program beyond COVID-19 vaccines and signaling broader momentum in the field of mRNA cancer therapies.
The FDA approved Moderna's mFLUSIVA (mRNA-1010) on August 5, 2026, making it the first mRNA-based flu vaccine for adults 50 and older TechTimes. The same month, Moderna and Merck reported stunning Phase 3 results for intismeran autogene, a personalized mRNA cancer vaccine that cut melanoma recurrence risk by nearly half TechTimes. The dual breakthroughs sent Moderna's stock soaring 177% in a single day, adding $45 billion to the company's market value and marking a major pivot away from COVID-19 vaccines toward oncology and seasonal respiratory diseases.
The melanoma trial enrolled 1,137 high-risk patients and showed the mRNA vaccine combined with Merck's Keytruda delayed cancer recurrence and spread Louisiana Radio Network. Meanwhile, mFLUSIVA demonstrated 26.6% relative superiority over standard flu shots in a study of over 40,000 adults. Both approvals validate Moderna's platform technology and suggest the company is entering a new phase as demand for COVID-19 shots fades Bend Bulletin.
How Personalized Cancer Vaccines Target Individual Tumors
Intismeran autogene works by removing and sequencing each patient's melanoma tumor after surgery. Moderna then designs a custom mRNA vaccine targeting up to 34 unique mutations in that specific tumor. The vaccine trains the immune system to recognize and destroy cancer cells with those exact mutations. This patient-specific approach differs sharply from older cancer vaccines that used generic antigens on late-stage patients Louisiana Radio Network.
In the Phase 3 trial, patients received the personalized vaccine plus Keytruda after surgery. Long-term Phase 2b data showed a 49% lower risk of recurrence or death and a 59% lower risk of distant spread compared to Keytruda alone TechTimes. Side effects were mild: fatigue and injection-site pain occurred in about 60% of recipients, with chills in roughly 51%. No Grade 4 or 5 treatment-related events were reported Press of Atlantic City.
mFLUSIVA Offers Faster Route to Match New Flu Strains
Traditional flu vaccines rely on eggs or cell cultures. Production takes six months or longer, and manufacturers often guess wrong about which strains will circulate. mFLUSIVA uses mRNA, which can be manufactured and updated in weeks. This speed advantage lets Moderna adapt quickly if new flu variants emerge Bend Bulletin.
The pivotal trial tested mFLUSIVA in over 40,805 adults across 11 countries. The vaccine showed 26.6% relative superiority to standard-dose shots at preventing RT-PCR-confirmed flu-like illness TechTimes. The FDA granted accelerated approval for ages 65+ based on a separate U.S. immunogenicity study of over 2,900 participants. Standard availability for the 2026–2027 flu season is expected Bend Bulletin.
Wall Street Erupts as Moderna's Oncology Pivot Validates mRNA Platform
On August 19, 2026, Moderna's stock jumped from roughly $25 billion in market value to nearly $69 billion. The single-day surge squeezed short sellers holding a 13% position, costing them $4.8 billion in paper losses Press of Atlantic City. CEO Stéphane Bancel called the moment historic, saying the company is "helping turn that vision into reality" after years of pursuing personalized mRNA cancer therapy TechTimes.
Analyst enthusiasm was clear. Tyler Van Buren at TD Cowen called the data a "landmark moment," while Trung Huynh at RBC Capital Markets called it "a major win" Press of Atlantic City. However, Wall Street's consensus price target remained at $74.54—far below the $174.38 closing price. Skeptics note Moderna lost $3.15 billion over the past year and that final overall survival data has not yet been disclosed Global Research.
What's Next: Expansion Into Other Cancers and Respiratory Combinations
Moderna and Merck plan to discuss intismeran autogene with global regulators in coming months. Clinical trials are already underway testing the vaccine in non-small cell lung, bladder, and kidney cancers. The success in melanoma suggests the approach could work across multiple tumor types. This marks a fundamental shift from single-use late-stage treatments to individualized post-surgery adjuvant therapy TechTimes.
The dual breakthroughs position Moderna as a diversified biotech company moving beyond COVID vaccines. Seasonal flu shots and personalized cancer therapies represent higher-margin, longer-term revenue streams. Industry observers say the melanoma win has reignited enthusiasm for the entire mRNA cancer vaccine field Bend Bulletin, signaling that the technology platform—not just pandemic response—is the true value driver.
Sentiment
Mostly PositivePublishers
35
Articles
161
Reach
196
